UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011971
Receipt number R000013982
Scientific Title Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group study
Date of disclosure of the study information 2013/11/01
Last modified on 2017/10/09 15:20:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group study

Acronym

JALSG-STIM213 Study

Scientific Title

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group study

Scientific Title:Acronym

JALSG-STIM213 Study

Region

Japan


Condition

Condition

Chronic Myeloid Leukemia Chronic phase

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To evaluate successful of treatment free remission of imatinib discontinuation in patients with chronic myelogenous leukemia in the chronic phase who continued a complete molecular response for at least 2 years

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

MMR rate at 12 M after discontinuation of treatment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

discontinuation of imatinib

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)MajorBCR-ABL positive CML-CP
2)Imatinib treatment more than for 3 years
3)Sustained CMR more than for 2 years
4)Patients who can attend the clinical study site in accordance with the pre-defined schedule.
5) Written informed consent from the subject (from the legal representative if the subject is under 20 years old).
Criteria after Screeing test
1) confirmed MR4.5 by IS-PCR

Key exclusion criteria

1)Patients with a history of treatment by the other TKI.
2)Patients with a history of hematopoietic stem cell transplantation.
3)Patients who have had blast crisis or accelerated CML.
4) Patients who have lost CMR during imatinib treatment.
5)Patients who have discontined imatinib treatment because of poor adherence.
6)Patients who do not want to re start imatinib after lost of MMR.
7)Other patients whom the investigator considers to be unsuitable for participation in the study.

Target sample size

62


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Naoto Takahashi

Organization

Akita Univ.

Division name

Dept. Hematology

Zip code


Address

1-1-1 Hondo, Akita city, Akita

TEL

018-884-6115

Email

naotot@doc.med.akita-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Naoto Takahashi

Organization

Akita Univ.

Division name

Dept. Hematology

Zip code


Address

1-1-1 Hondo, Akita city, Akita

TEL

018-884-6115

Homepage URL

http://www.jalsg.jp/

Email

naotot@doc.med.akita-u.ac.jp


Sponsor or person

Institute

Japan Adult Leukemia Study Group

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labor and Welfare

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 11 Month 01 Day


Related information

URL releasing protocol

http://www.jalsg.jp/clinical-research/now

Publication of results

Published


Result

URL related to results and publications

https://www.springermedizin.de/deeper-molecular-response-is-a-predictive-factor-for-treatment-f/1507

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 11 Month 06 Day

Date of IRB


Anticipated trial start date

2013 Year 11 Month 30 Day

Last follow-up date

2015 Year 04 Month 30 Day

Date of closure to data entry

2017 Year 04 Month 30 Day

Date trial data considered complete

2017 Year 06 Month 30 Day

Date analysis concluded

2017 Year 07 Month 31 Day


Other

Other related information



Management information

Registered date

2013 Year 10 Month 06 Day

Last modified on

2017 Year 10 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013982


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name